Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research note issued to investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, February 26th.

Minerva Neurosciences Trading Up 5.2 %

Shares of Minerva Neurosciences stock opened at $1.60 on Friday. The company’s fifty day simple moving average is $1.66 and its two-hundred day simple moving average is $2.08. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $3.69. The company has a market cap of $11.19 million, a P/E ratio of -3.64 and a beta of -0.09.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. Analysts predict that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Minerva Neurosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Apella Capital LLC bought a new stake in Minerva Neurosciences during the 1st quarter valued at about $35,000. Citadel Advisors LLC grew its holdings in shares of Minerva Neurosciences by 49.5% during the fourth quarter. Citadel Advisors LLC now owns 25,764 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 8,525 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of Minerva Neurosciences by 60.0% during the fourth quarter. Northern Trust Corp now owns 36,878 shares of the biopharmaceutical company’s stock valued at $82,000 after acquiring an additional 13,829 shares in the last quarter. 34.56% of the stock is currently owned by institutional investors.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.